EC

ABSTRACT: The aim of the present study is to design and evaluate the controlled release Glyburide trilayer matrix tablets, to achieve zero-order drug release for sustained plasma concentration. Matrix tablets were prepared by direct compression whereas three-layer tablets were prepared by compressing polymer barrier layers on both sides of the core containing the drug. Formulations were prepared by using different grades of hydroxy propyl methyl cellulose and Ethyl cellulose. Based on the evaluation parameters, drug dissolution profile and release drug kinetics HF16 was found to be optimized formulation. These results also demonstrated the suitability of three-layered tablet formulation of Glyburide to provide controlled release for prolonged period and improved linearity for Glyburide in comparison to marketed product in the management of Diabetes. Keywords: Glyburide, Type II Diabetes, HPMC Grades, EC, MCC, Release order kinetics.  

In the present study, an attempt was made to prepare and evaluate matrix tablets of Ondansetron HCl using HPMC, EC and Eudragit for Sustained release of Ondansetron HCl. The matrix tablets were prepared by wet granulation method. All the formulations are evaluated for the Hardness, Friability, Weight variation, Drug Content, In-Vitro Drug Release. The weight variation and drug contents of all the tablets were found to be uniform with the low SD values. The FTIR study indicated that the drug is stable in the formulations. The prepared matrix tablets were capable of releasing the drug for 12 hours depending upon the formulation variables. The tablets prepared with HPMC and Eudragit combination have shown higher drug release Drug release mechanism followed non-Fickian transport from both the polymers matrices. The drug released from the formulation is depends on the concentration of the polymers.

The main objective of the present investigation was to formulate and evaluate chronomodulated pulsatile drug delivery system of Trimetazidine Hydrochloride which was aimed to release the drug after lag time (6 hrs) in order to mimic circardian rhythm of Angina Pectoris.Preformulation studies and compatibility studies were carried out for drug and excipients. Core tablet was prepared by direct compression using sodium starch glycolate as superdisintegrant and press coated with different polymer & varying its ratio. Further prepared tablets were optimized using 32 full factorial design. Nine batches were prepared varying the amount of polymer and ratio of polumer (HPMC K4M: EC) and they were evaluated for precompressional and postcompressional tests. Optimized batch was derived statistically using desirability function (Minitab 17).The Model was validated by formulating the check point batch. Accerelated stabilitiy study was carried out of optimized batch. Preformulation and compatibility studies was carried out using FTIR , DSC which shows satisfactory results, no interaction was found between drug and excipients. Press coating of core tablet with the combination of HPMC K4M and EC was found to be providing the desired release. Results of precompressional and postcompressional was found to be within the limits. Varying  the amount of coating and ratio of polymer have significant effect on lag time(Y1) as well as on time required for 90% drug release (Y2).Optimized batch shows lag time of 6 hrs followed by complete release within 1 hrs which is desiered in case of pulsatile delivery. No significant bias was found between predicted and observed value of check point batch.The data of stability study revealed that the optimized formulation is stable. Pulsatile drug delivery system of Trimetazidine Hydrochloride for chronomodulated therapy can be prepared by press coating technique using 200 mg of coating and HPMC K4M:EC(10:90) ratio of polymer which will provide lag time of 6hrs and complete release within 1 hrs.

A controlled release system is designed to provide constant or nearly constant drug levels in plasma with reduced dose, frequency of administration and fluctuations in plasma concentrations via slow release over an extended period of time.One of the least complicated approaches to the manufacture of controlled release dosage forms involves the direct compression of blend of drug, retardant material and additives to formulate a tablet in which the drug is embedded in a matrix of the retardant. Gabapentin is an anti epileptic drug used for the treatment of epileptic seizures and in treatment of post therapeutic neuralgia.  In this study controlled released Gabapentin matrix tablets were prepared by using different matrix forming polymers which include hydrophilic polymers like HPMC K15M, HPMC K100M, Xanthan gum and hydrophobic polymer like Ethylcellulose in various ratios to retard the release of drug upto 12hrs. The formulations containing the combination of hydrophilic and hydrophobic polymer combinations (HPMC K100M with Ethycellulose) and the formulations prepared with the combination of two hydrophilic polymers of synthetic and natural origin (HPMC K100M with Xanthan Gum) exhibited maximum drug release(99%) upto12hrs during in vitro dissolution studies with optimum swelling characteristics.